OLMA Olema Pharmaceuticals

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) --  (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

H.C. Wainwright 3rd Annual BioConnect Investor Conference

Date: Tuesday, May 20, 2025 at 4:30 p.m. ET

Format: Fireside Chat

Location: New York, NY

T.D. Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO and EHA

Date: Tuesday, May 27, 2025 at 5 p.m. ET

Format: Fireside Chat

Location: Virtual

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at .

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .

Media and Investor Relations Contact

Courtney O’Konek

Vice President, Corporate Communications

Olema Oncology



EN
09/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Olema Pharmaceuticals

 PRESS RELEASE

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Prog...

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting 90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm CT / 10:00am–1:00pm ET SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted t...

 PRESS RELEASE

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Jefferies Global Healthcare ConferenceDate and Time: Wednesday, June 4, 2025 at 11:40 a.m. ETFormat: Fireside ChatLocation: New York, NY Goldman Sachs 46th Annual Global Healthca...

 PRESS RELEASE

Olema Oncology Reports First Quarter 2025 Financial and Operating Resu...

Olema Oncology Reports First Quarter 2025 Financial and Operating Results Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstrating anti-tumor activity i...

 PRESS RELEASE

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) --  (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference Date: Tuesday, May 20, 2025 at 4:30 p.m. ETFormat: Fireside Chat Location: New York, NY T.D. Cowen 6th Annual Oncology Innovati...

 PRESS RELEASE

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch